SCHEMBL1836758

SCHEMBL1836758

FC(F)(F)c1ccc(Oc2ccccc2P(c2ccccc2)c2ccccc2Oc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39
KIF11 P52732 1/20 0.39
MAPK14 Q16539 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
RAB9A P51151 1/20 0.37
CACNA1B Q00975 4/20 0.37
CACNA1H O95180 1/20 0.37
SLC6A4 P31645 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
LTA4H P09960 1/20 0.36
EPHX2 P34913 1/20 0.36
SLC6A2 P23975 2/20 0.35
SLC6A3 Q01959 2/20 0.35
KCNK2 O95069 1/20 0.35
KCNH2 Q12809 1/20 0.35
CACNA1C Q13936 1/20 0.35
RIPK1 Q13546 1/20 0.35
PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023411 0.90 L3MBTL1 (0.41) ALDH1A1TSHRKIF11MAPK14L3MBTL1
SCHEMBL1838565 0.83 TSHR (0.44) ALDH1A1TSHRL3MBTL1SLC6A4KMT2A
SCHEMBL10976813 0.79 TSHR (0.44) ALDH1A1TSHRL3MBTL1SLC6A4KMT2A
SCHEMBL28638978 0.79 L3MBTL1 (0.52) ALDH1A1TSHRKIF11MAPK14L3MBTL1
SCHEMBL1840334 0.79 HTR2A (0.45) ALDH1A1L3MBTL1SLC6A4MEN1KMT2A
SCHEMBL1834449 0.78 NFE2L2 (0.42) ALDH1A1TSHRKIF11RAB9AMEN1
SCHEMBL1840257 0.73 LTA4H (0.50) ALDH1A1TSHRL3MBTL1SLC6A4KMT2A
SCHEMBL14082040 0.73 ALDH1A1 (0.59) ALDH1A1TSHRKIF11RAB9A
SCHEMBL254896 0.73 TSHR (0.59) ALDH1A1TSHRKIF11MAPK14SLC6A4
SCHEMBL9854377 0.73 ALDH1A1 (0.59) ALDH1A1TSHRKIF11RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321244-B1 IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-21 EP disclosed
US-8558030-B2 Process for telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2013-10-15 US disclosed
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) 2011-06-09 US disclosed
EP-2321244-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2011-05-18 EP disclosed
WO-2010019360-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE HRH3, HRH4, TELO2 ALDH1A1 2964/4885TSHR 1049/4885KIF11 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.